US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals
Development of the model DFLs was a first for agency. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.
You may also be interested in...
With no end to the partial shutdown in sight, public safety concerns are mounting along with anxiety among furloughed employees. FDA Commissioner Gottlieb remains a vibrant presence on social media, working to maintain staff morale and reassure the public that critical agency functions carry on.
US FDA has enough carryover funding for another month of operations, Commissioner Gottlieb says, potentially endangering late February and March review goals.
Now that US FDA is about to complete label comprehension study, sponsors seem more positive about OTC versions of naloxone products.